| Names | |
|---|---|
| Preferred IUPAC name | 3-(E)-3-phenyl-2-propenyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| Other names | Cilacarn Cilacar Cilnidip Atelec Cilni |
| Pronunciation | /ˌsɪlˈnɪdɪpiːn/ |
| Identifiers | |
| CAS Number | 132203-70-4 |
| Beilstein Reference | 1562203 |
| ChEBI | CHEBI:59139 |
| ChEMBL | CHEMBL1172430 |
| ChemSpider | 21560827 |
| DrugBank | DB09230 |
| ECHA InfoCard | 03a4147e-40e6-4ab2-93fb-e4c2aaca5a32 |
| EC Number | 135393-81-4 |
| Gmelin Reference | 929131 |
| KEGG | D08973 |
| MeSH | D064264 |
| PubChem CID | 53735 |
| RTECS number | GV8788000 |
| UNII | 0X8A9U8IYXP |
| UN number | UN number not assigned |
| Properties | |
| Chemical formula | C27H28N2O7 |
| Molar mass | 492.567 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Practically insoluble in water |
| log P | 3.64 |
| Acidity (pKa) | 8.45 |
| Basicity (pKb) | 8.69 |
| Magnetic susceptibility (χ) | -75.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.416 |
| Dipole moment | 3.43 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 427.1 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -1342.8 kJ/mol |
| Pharmacology | |
| ATC code | C08CA13 |
| Hazards | |
| Main hazards | May cause hypotension, dizziness, headache, palpitations, and, rarely, allergic reactions. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | lactose-free, gluten-free |
| Signal word | Warning |
| Hazard statements | No Hazard Statements. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Use only as directed by your physician. Store in a cool, dry place away from light and moisture. Do not use after the expiration date. |
| Flash point | 158.6 °C |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Cilnidipine: **>2000 mg/kg (rat, oral)** |
| PEL (Permissible) | 0.05 mg/m³ |
| REL (Recommended) | 10 mg once daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Nicardipine Nifedipine Amlodipine Lacidipine Felodipine Isradipine Lercanidipine Benidipine Manidipine |
| Item | Details | Manufacturer Commentary |
|---|---|---|
| Product Name & IUPAC Name |
Cilnidipine IUPAC: 3-(2-Methoxyethyl) 5-[(E)-3-phenyl-2-propenyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
The naming convention reflects the structural specificity embedded in 1,4-dihydropyridine calcium channel blockers. Selection of nomenclature in documentation remains consistent with regulatory filings. Systematic IUPAC assignment supports traceability across synthetic and analytical workflows. |
| Chemical Formula | C27H28N2O7 | Molecular formula informs by-impurity profiling and theoretical mass balance during synthesis. In production scale, tracking atom economy using definitive formulae is essential for process yield calculations and impurity generation rationalization. Reactive impurities and intermediates are mapped against the core formula backbone to inform purification design. |
| Synonyms & Trade Names | 2-Methoxyethyl (2E)-3-phenyl-2-propen-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Atelec; Cinalong | Regulatory submissions, pharmacopoeial referencing, and import/export documentation often require synonym discovery during due diligence to avoid misidentification. Broad synonym use impacts packaging compliance and hazard communication in multi-jurisdictional shipping. |
| HS Code & Customs Classification |
HS Code: 29349900 (Other heterocyclic compounds) |
Classification under 29349900 fits global customs frameworks for nitrogen heterocyclics not specified elsewhere. The accuracy of HS allocation directly affects import duty, regulatory import permissions, and batch traceability across global supply chains. Product grade sometimes determines tariff eligibility or documentation burden, especially for pharmaceutical use versus fine chemical intermediates. |
In continuous production batches, Cilnidipine appears as a fine crystalline powder. Color and form often reflect the quality of purification and raw material lot; subtle yellow to pale off-white hues arise from distinct synthesis and isolation pathways. Color grade is primarily monitored in final release for oral pharmaceutical use. Odor is typically neutral; deviations may signal contamination or incomplete solvent removal. The melting point range, as measured in controlled lab trials, demonstrates batch purity but can shift slightly with impurity level or polymorph distribution. Boiling and flash points have no practical measurement value due to decomposition before volatilization under ambient pressure, a trait common to this family of dihydropyridine compounds. Bulk density varies by micronization, impacting formulation flow and blending.
Chemical stability relies on control of moisture, temperature, and protection from light. Dihydropyridine rings undergo slow oxidation, particularly under prolonged exposure to UV or elevated humidity. Acid or base contact can degrade the ester moiety, generating by-products. Storage is evaluated for hydrolysis and oxidation risks, with low humidity and light-exclusion as routine safeguards. Reactivity with formulation excipients is evaluated case-by-case depending on final dosage form and customer requirements.
Solubility in water is extremely limited due to the hydrophobic nature of the core structure; processing often employs suitable organic solvents, such as ethanol or dichloromethane, for intermediate purification stages. For analytical assay and impurity profiling, stock solutions are commonly prepared using validated mixtures, as solubility and stability profiles shift with grade, polymorph, and solvent history.
Specifications reflect intended application. Pharmaceutical-grade Cilnidipine receives the tightest limits on heavy metals, related substances, and polymorphic content. Technical or R&D grades follow different baselines adapted to formulation needs and regulatory context. Final specification alignment often considers both internal quality metrics and the customer’s registration or regulatory submission requirements.
The impurity profile is monitored throughout process validation and batch release. Sources of impurities trace to starting materials, side reactions, incomplete conversions, solvent residues, and environmental factors. Process changes or scale-up can impact impurity profiles; labs routinely compare chromatographic fingerprints and adjust process controls as part of lifecycle management. Upper impurity limits are set following ICH guidelines for pharmaceutical grade, or according to internally developed safety assessments for non-pharmaceutical grades.
Testing utilizes validated HPLC for identity, purity, and quantitation, with methods selected and adjusted based on intended use and customer submission region. Additional testing covers water content, residue on ignition, and particle size distribution if relevant. All release testing aligns with current regulatory norms or, where such norms are absent, with mutually agreed technical contracts.
Raw material selection prioritizes batch reliability, traceability, and impurity burden. Key starting reagents include dihydropyridine derivatives, acyl chlorides, and nitroaromatic intermediates, sourced from globally qualified suppliers subject to change control audits. Sourcing logic considers regional raw material quality variance and backward integration prospects.
Synthesis commonly proceeds via multi-step routes, utilizing protected dihydropyridine scaffolds and controlled acylation or esterification. Reagent ratios, solvent choice, and temperature setpoints reflect impurity minimization and throughput optimization goals. Hydrogenation and selective hydrolysis steps require catalyst activity fine-tuning to avoid over- or under-conversion. Route-specific steps influence downstream purity and cost, and are reviewed for yield and safety across each campaign.
Key control points include temperature profile, reaction pH, addition rates, and endpoint analytics (often in-line or at-line by HPLC or TLC). Intermediate isolation/crystallization steps remove process-related impurities and reduce solvent load. Final purification typically employs recrystallization and filtration, with selection of conditions to balance throughput and exacting purity. Quality assurance units review data for each stage and intervene when trends indicate drift or deviation.
In-process controls monitor yield, impurity peaks, and physical parameters throughout. Batch release combines final specification verification, full review of process records, and retention sample inspection. Pharmaceutical applications are subject to additional full compliance audits and data traceability.
Cilnidipine possesses both ester and dihydropyridine functional groups. Laboratory and scale-up chemists exploit these sites for potential derivative synthesis or impurity investigation. Hydrolysis (acid/base catalysis), oxidation (air, peroxide, UV), and alkylation reactions often occur if process conditions drift. Such reactivity dictates purification choice and guides impurity profiling.
Process steps call for moderate temperature (usually below reflux for each stage to minimize degradation), carefully controlled catalyst use, and strict moisture exclusion at key points. Organic solvents are chosen for both solubilization and minimal by-product formation. Waste management systems factor solvent recovery and neutralization into route design.
The base structure supports modification to other calcium channel blockers or analytical standards for related substance testing. Selection of derivatives depends on in-house route flexibility and intellectual property considerations in the pharma sector.
Bulk Cilnidipine is protected from heat, direct light, and moisture ingress. Warehouse teams use sealed, inert gas-purged drums or double-poly lined fiber drums where long-term stability is critical. Desiccant use inside drums or storage rooms is routine depending on season and ambient humidity. Retrospective analysis of returned samples guides permissible storage duration and light exposure benchmarks.
Compatible storage solutions favor high-density polyethylene or lined fiber containers; glass may be used for high-purity sublots but presents breakage concerns for industrial-scale movement. Storage testing monitors for container-extractable components and container closure system interactions.
Shelf life depends on storage conditions and product grade. Typical degradation becomes visible through color darkening, tackiness, or abnormal odor. QC regularly screens for early degradation markers and reviews shelf life allocations based on real-time and accelerated stability tests.
The classification aligns with observed toxicity and acute hazard data. Staff monitor for updates to classification as regulatory and scientific consensus evolves. Final label elements are updated at each regulatory review interval and labelling is batch-specific for pharma shipments.
Hazard management reflects chronic toxicity studies and workplace exposure trials. Handling statements in the facility focus on minimizing dust inhalation and chemical contamination of skin or mucosa. Emergency instructions are reviewed with each incident or audit cycle.
Toxicology studies guide batch release limits for process impurities and inform respirator and protective clothing requirements in production and packaging. Ingestion risks restrict application to regulated oral forms; dermal and inhalation risks are managed through primary containment in bulk handling.
Worker exposure standards reflect both internal plant experience and external regulatory values for comparable compounds. Handling guidance draws on dust control measures, dedicated exhaust, selective automation at weighing/charging, and strict segregation from reactive chemicals.
Bulk manufacturing of Cilnidipine relies on consistent procurement of key raw materials, especially 2-nitrophenylacetonitrile and the appropriate pyridine derivative. Availability tracks closely with global supply chains for advanced intermediates, which can occasionally face bottlenecks due to upstream shortages or shifts in agrochemical allocations in India and China. Flexibility in route selection supports higher output during periods of stable raw material sourcing. Typical campaign sizes depend on projected orders and downstream formulation partner schedules. We scale batch execution plans in alignment with annual forecasts and customer call-offs, prioritizing GMP or equivalent-controlled grades by contract duration and priority customer status.
Standard lead times for Cilnidipine range from 4 to 8 weeks from PO, influenced by current campaign planning, available line time in finishing, and final QA release slotting. GMP validation or lower impurity grades often require additional analytical turnarounds. The MOQ reflects not only the batch size tied to process economics, but also stability/losses in packaging and regulatory constraints. Customisation requests (purity, particle sizing, or packaging) may elongate prep and documentation timelines, so accurate upfront communication is essential.
Packaging strategies for Cilnidipine must maintain photostability and avoid cross-contamination. Common formats include lined fiber drums, HDPE bottles, and foil-pouched units, all compliant with moisture barrier standards. Pharmaceutical grades may be provided in componentized sub-lots for easier repacking under secondary QA. Custom primary packaging can be offered according to end-use risk assessment and customer audit findings, with clear assignment of shelf-life and retest time per lot release.
International shipment typically proceeds under EXW or FCA incoterm, with internal transit measures calibrated to prevent temperature excursions and humidity ingress. Documents include COA, MSDS, and full lot traceability sets. Advance payment is standard for new business, though long-term partners may opt for net settlement terms upon approval. Compliance with dual-use export controls or precursor declarations is strictly managed for sensitive markets.
Material cost for Cilnidipine is governed by the market for aromatic nitriles and specialty pyridines. Global price swings arise from changes in feedstock benzene/acetone values, environmental crackdowns on intermediate plants, and production reallocation between pharma and crop-protection sectors. Regulatory or political trade measures in China, India, and the EU periodically affect available volumes and landed costs for key intermediates. Sourcing strategy for each campaign weighs single-source risk against cost efficiency, impacting bottom-line pricing.
Price structure reflects both grade and compliance documentation. Purity thresholds for standard industrial, technical, and pharma API grades set the baseline. Impurity requirements—mainly regarding residual solvents, elemental impurities, or optical/particle sizing—are tiered by customer application, with tightest targets commanding a premium. Custom packaging (clean room compatible or tamper-evident seals) increases finish unit cost. Full audit trail or DMF/COS-backed material bears a significant price delta over non-pharma grades.
Worldwide demand for Cilnidipine has tracked the increasing reliance on dihydropyridine-class antihypertensive drugs, particularly in large generics markets. India and China remain central to both production volume and API demand, while the EU, Japan, and the US specify higher-level regulatory compliance. Japanese market often dictates the tightest impurity and traceability constraints, while India remains price sensitive but commits to larger volume contracts.
The US and EU markets exhibit stable but incremental growth, with focus on quality-by-design integration and traceable supply chains. Specification drift and regulatory tightening post-GMP audits can prompt sudden demand for higher compliance batches. Japan’s consistent demand for sub-threshold impurity lots keeps upward pressure on pricing for higher grades. In India and China, intermittent government procurement and shifting generic launch cycles drive periodic surges in API tendering and spot pricing.
Looking toward 2026, price volatility for Cilnidipine will correlate to ongoing regulatory harmonization, tightening specifications on residual impurities, and global supply pressures for nitrile intermediates. Demand from emerging economies and evolving registration pathways will sustain market volume. Upward price drift is probable in pharma-qualified API grades as more stringent safety and traceability norms come into effect. Technical or industrial grades may see less volatility, provided upstream supply remains uninterrupted.
Forecasts integrate historical contract prices, market intelligence from supplier audits, public regulatory filings, and internal cost tracking, combined with quarterly inputs from key regional formulation partners. No forward prices are committed outside contract scope.
Realignment of supply networks has followed stricter Chinese environmental audit cycles, with several upstream plants facing temporary shut-downs. This has produced sporadic tightness in advanced intermediate flows, affecting both availability and spot prices through late 2023 and early 2024.
Recent pharmacopoeia changes in both the USP and JP monographs for Cilnidipine reference increasingly strict impurity thresholds, particularly for genotoxic and nitrosamine risks. Implementation schedules impose new process and analytical checkpoints on qualifying API batches for regulated markets.
Plant teams have increased engagement with upstream partners, shifting to dual-source validated streams and enhanced impurity profiling. Upgrades in in-process control laboratories have shortened QA disposition cycles for each batch. Proactive holding of safety stock for critical intermediates is favored for committed supply contracts into regulated markets. Close monitoring of regulatory notifications from major health authorities enables earlier batch upgrades or campaigns as needed to avoid market disruption.
Cilnidipine, a dihydropyridine calcium channel blocker, supports several sectors driven by demand for cardiovascular pharmaceuticals. Most production is focused on providing active pharmaceutical ingredient (API) for solid oral dosage forms, particularly antihypertensive therapies. Specialty applications include research use in academic pharmacology, reference substance preparation, and, in some regions, compounding pharmacies. Each end-use presents distinct priorities for impurity control and physical characteristics. Commercial-scale manufacture emphasizes reproducible crystal form, solvent residue minimization, and trace impurity management. Laboratory and research purchasers look for reliable batch documentation and straightforward reconstitution.
| Application | Recommended Grade | Key Grade-Sensitive Properties |
|---|---|---|
| Solid Oral Dosage Form (API) | Pharmaceutical Grade | Polymorphic consistency, low residual solvents, strict related substance thresholds, defined particle size range, documentation for DMF/CEP |
| Formulation R&D/Reference Standard | Analytical/Reference Grade | Batch traceability, highly purified, impurity profile characterization, certificate of analysis showing LC-MS/HPLC results |
| Academic Research/Application Chemistry | Technical/Bulk Grade | Basic purity suitable for non-therapeutic testing, less stringent impurity limits, smaller packaging |
Pharmaceutical use places primary importance on low levels of specified impurities, as defined by regional pharmacopoeias and customer registration needs. For example, related substances, heavy metals, and solvent residues drive batch segregation. Polymorphism and particle size can influence tabletting and solubility performance; these characteristics get priority adjustments according to customer processing route (direct compression, granulation, etc.). Analytical and reference grades demand consistent high purity and confirmed identity, ensuring results across labs. R&D and development applications sometimes accept wider impurity profiles but request clear batch histories and representative data.
Start with the finished use. Oral solid API supply for regulated pharmaceutical production calls for conformance with pharmacopoeial and regulatory standards. Pre-formulation or research needs permit more flexibility with respect to impurity controls. The rationale for purchase should always be matched to grade commensurate with the intended use: treatment, analysis, or investigational work.
Pharmaceutical manufacturing in most countries requires DMF support, CEP registration, or at a minimum, proof of compliance with the local pharmacopoeia. Some projects target markets with unique mandatory specifications for elemental impurities, nitrosamines, or other risk factors. Early communication of official requirements allows batch planning, retention sample setup, and expedited documentation assembly.
API use compels strict purity, primarily based on limiting known and unknown impurities to below thresholds set by ICH or national standards. Research grades prioritize purity and identity, typically accepting wider specification bands for minor unknown impurities unless otherwise requested. Particle morphology and moisture often affect downstream blending and stability, so should be discussed in advance, especially for direct compression routes.
Larger volume requests benefit from tighter batch-to-batch consistency, as standardization is managed through process controls and intermediate blending. Research-scale projects sometimes accept multi-lot composites or technical grades, balancing purity and documentation with budget efficiency. For high-throughput clinical programs, a single batch covering multiple site requirements streamlines regulatory alignment and reduces supply chain risks.
Process formulation validation, method development, or stability trials often require a pre-shipment sample before bulk order placement. This enables internal assessment of physical properties such as flowability, dissolution, solubility, and compatibility with excipients. The manufacturer’s technical team can support with sample documentation and historical QC records to ensure fit-for-purpose supply.
From the production floor to finished packaging, our approach relies on an established quality system benchmarked by internationally recognized management standards. Production of cilnidipine aligns with our validated internal quality management protocols. Facilities maintain persistent compliance, verified through periodic external audits and continuous self-assessment routines, helping us address deviations through documented corrective action. Routine training ensures all operators and technical staff understand protocol revisions and batch control logic. Adherence to these structures remains foundational for traceability and recall accountability.
For cilnidipine, requests for Drug Master File (DMF) support, process documentation for regulatory filings, and compliance audit cooperation are handled by our technical documentation team. Our manufacturing lines can support pharmaceutical-registered, food-grade, or industrial-grade designations, based on customer segment and local authority requirements. Site-specific registrations, such as GMP or other country/local regulatory filings, are strictly batch-record contingent and grounded in the actual operating region. Certification availability varies: for regulated-markets, additional process and system inspections may apply. Our documentation reflects real audit and inspection outcomes, without generic claims.
Every shipment of cilnidipine leaves the facility with a complete product dossier: Certificate of Analysis (CoA), batch production records, and, upon formal request, Process Validation and Cleaning Validation summaries. Analytical results represent actual lot and specification sheets. For product change notifications, all affected customers receive bulletins outlining material, process, and/or packaging modifications as stipulated by our management of change (MoC) protocol. The technical file can be tailored to customer regulatory requirements when notified in advance. For industrial and regulated pharma supply, audit reports and additional process control documents may be released per confidentiality agreement.
The production scheduling for cilnidipine uses both forecast-driven and order-committed systems. Fluctuations in upstream material supply, batch-to-batch yield optimization, and final packaging requirements are reviewed quarterly to prioritize longstanding customers and high-volume arrangements. For project-based or spot purchasing, we offer allocation based on available free capacity after standing orders. Business cooperation terms, contract sizes, and delivery schedules reflect real supply capability; abnormal demand spikes, raw material shortages, or force majeure events follow transparent notification and allocation policy. Flexible collaboration may include consignment stock, third-party warehousing, or just-in-time delivery, defined per actual negotiation outcome.
Core capacity is determined from historical monthly output, validated maintenance cycles, and engineering bottlenecks unique to our cilnidipine synthesis route. Batch capacity, reprocessing tolerance, asset downtime, and purification infrastructure all impact absolute throughput. In process scale-ups or expansion, new validation runs are logged independently. Where regional demand forecasts indicate sustained growth, we prioritize parallel processing and raw material redundancy to buffer supply interruptions. Customers with critical delivery requirements may access monthly capacity statements and buffer stock planning upon agreement.
Sample requests undergo standard technical evaluation: application scenario, required grade specification, and anticipated order volume guide the sample submission protocol. Small lots from representative commercial batches are retained for this purpose to ensure property matches. All samples ship with analytical data reflecting the specific sample lot—not generic values— and storage or stability recommendations are detailed subject to the product grade and downstream application needs. Restricted samples for specific regulatory jurisdictions or customer segments may involve additional compliance vetting.
For cilnidipine, business cooperation models address partner planning needs: long-term framework agreements, volume-based pricing, and multi-shipment scheduling suit demand variability and inventory fluctuation. Consignment models or customer-specific reserved stock arrangements exist for partners with demonstrated purchase regularity. For new projects, phased supply ramp-up or pilot batch collaboration supports commercialization without overcommitting inventory. Terms around minimum order quantity, expedited dispatch, backorder management, and recall responsiveness all depend on risk assessment, grade criticality, and prior performance history. This flexibility follows open technical exchange with procurement and technical teams to ensure actual plant feasibility matches declared agreement terms.
| Certification / Support Item | Manufacturing Department Note |
|---|---|
| Quality Management Certification (e.g., ISO) | Internal audits benchmarked and recertified according to internationally recognized standards. Actual certificate type and issuing authority confirmed upon request for each site. |
| Regulatory Registration | Documented according to region and product grade; supported by technical files per customer specification. |
| Analytical CoA and Batch Records | Lot-specific data issued for every shipment; atypical analytical findings prompt pre-dispatch technical clarification. |
| Sample Provision | Controlled by technical and commercial evaluation; sample retention and tracking logged for traceability. |
| Flexible Supply Agreements | Cooperation plans tailored by historical demand, buffer planning, and real plant output capability. |
Development continues to focus on optimizing process yields and impurity control along different synthetic routes. Catalytic efficiency, solvent recovery systems, and process intensification attract attention for both cost and environmental reasons. Regional R&D groups prioritize impurity profiling methods and documentation that align with evolving pharmacopoeial standards, as regulatory expectations grow more stringent for trace-level reporting.
Interest has grown in formulating Cilnidipine in fixed-dose combinations, particularly for multi-drug regimens. As generic entry accelerates, some developers have shifted efforts toward modified-release and patient-adherence formulations, which require alternate polymorph management and excipient compatibility assessment in scale-up. Veterinary and veterinary-adjacent applications remain minimal, with most R&D directed at oral solid dosage for human hypertension therapy.
Inconsistent particle size and flowability between manufacturing batches represent recurring challenges, especially during direct compression. Synthesis routes with varied raw material supply chains display differences in polymorphic distribution and crystallinity, affecting downstream tablet performance. Recent advances in real-time NIR spectroscopy and online monitoring technologies have allowed earlier impurity detection, enabling process corrections before crystallization steps. Implementation varies by plant capacity and automation maturity.
Global demand is projected to track with antihypertensive class adoption and rising prevalence of cardiovascular disorders in key markets. Volume growth will likely concentrate in jurisdictions approving additional combination therapies or where local generics gain reimbursement status. Downward price pressure from increased competition is expected, which shifts production priorities toward capacity utilization and shorter turnaround times.
Manufacturing groups are phasing in continuous processing models for routine grades, with discrete batch operations preserved for high-purity or specialty batches required by some regulatory filings. Automation levels differ by plant age; newer sites embed inline PAT monitoring, reducing manual sampling. Solid-state form selection and polymorph risk mitigation are now built into the late-stage process design, in direct response to post-market recalls in this product class due to out-of-spec polymorphic transitions.
Solvent recycling stands central to the sustainability drive, supported by selection of greener solvents and energy-efficient chillers. Attention to reducing aqueous and organic waste discharge continues, especially as wastewater regulations tighten in several regions hosting bulk manufacturing plants. The technical focus falls on modifying steps that traditionally rely on halogenated intermediates or excess oxidant—phasing these out demands careful control of structure and yield.
Process and analytical support teams are available for detailed discussions around synthetic route modifications, scale-up risk assessment, and troubleshooting deviations observed in polymorph profile or impurity spectrum. Typical queries address adaptation of analytical methodologies to local regulatory expectations, grade-specific solubility, and compatibility in formulation development.
Recommendations for direct compression or granulation depend on product grade and particle properties required by the customer’s formulation process. Application support includes guidance on milling strategies, dryer discharge protocols, and excipient blending that preserve flow and compressibility. Customers developing combination products work with application scientists to align dissolution requirements and ensure homogeneity in low-dose blends.
Quality assurance teams handle customer concerns regarding batch-to-batch consistency, particle characteristics, and specific impurity thresholds according to regional monographs. Release criteria for each consignment are reviewed against both internal QC thresholds and customer contract parameters. Ongoing customer audits verify traceability back to raw material selection, documented in the batch DMR according to site quality protocols.
As a chemical manufacturer with decades of direct industry experience, our facility operates vertically integrated synthesis lines dedicated to Cilnidipine production. Each batch draws from strict process controls, beginning with core raw material selection handled under in-house oversight. Our teams standardize each synthesis step through dedicated reactors monitored round the clock for real-time quality parameters. With these systems in place, product consistency rises above market fluctuations or external disruptions. Technical staff monitor impurity profiles, particle size, and moisture levels at multiple stages. This ensures our partners, from formulation houses to finished dosage manufacturers, receive a robust active pharmaceutical ingredient without supply guesswork.
Cilnidipine serves as a cornerstone compound for advanced antihypertensive formulations in the pharmaceutical sector. Most customers operate high-volume manufacturing plants where every kilogram contributes to controlled dosage outputs. Our direct process management guarantees repeatability from lot-to-lot, a critical consideration when producing generic and branded formulations for regional and global markets. Downstream, contract manufacturers and repackers integrate our API into their own value chains, counting on a supply chain free from middlemen or blending ambiguities.
Consistency stems directly from our internal laboratory and quality assurance protocols. All critical control points, including crystal form, solvent residue, and heavy metal contents, are validated through advanced instrumentation calibrated to pharmacopeial standards. Each release comes with a full set of analytical data inspected by veteran chemists. Our quality department continuously reviews both trending data and customer feedback to tighten upstream controls. Over the years, we have supported numerous validation programs by sharing detailed process maps and representative samples drawn directly from scale production.
Industrial clients expect Cilnidipine in packaging that holds up through international transport and long-term storage. We manage a dedicated cleanroom packaging area. Customers select from multiple packaging formats, ranging from bulk fiber drums with double PE liners for high-volume users to smaller aluminum foil packs for pilot and niche requirements. Careful monitoring during filling, sealing, and labeling reduces the risk of contamination or misidentification. Direct logistics teams, equipped with on-site inventory management systems, coordinate regular dispatches to regional and global clients. This system supports both ongoing forecasted orders and urgent requests linked to shifts in market demand.
Our technical support draws on years of troubleshooting for industrial buyers. R&D teams at domestic and multinational groups frequently consult our in-house specialists to address solubility, stability, and upscaling challenges. Customers count on firsthand access to analytical method development, process validation documents, and regulatory query handling—all tracked by assigned managers with hands-on production experience. Each support request goes through our issue log and feedback process designed for resolution in real manufacturing environments, not just theoretical compliance.
Manufacturers working under regulatory scrutiny require transparent sourcing with documented process control. Cementing partnerships with direct producers eliminates unnecessary intermediaries and shields supply chains from sudden disruption or inconsistent sourcing practices. Distributors benefit from clear compliance documentation and on-record batch traceability, ensuring downstream partners meet regulatory timelines without last-minute delays. Procurement teams leverage negotiated contracts directly at the plant level, yielding firm delivery commitments and consistent technical support.
| Key Advantages | Direct Producer Benefit |
|---|---|
| Production Control | End-to-end oversight from raw material intake to final release |
| Batch Traceability | Full documentation and archive directly linked to plant systems |
| Supply Assurance | Stable, repeatable scheduling matched to ongoing customer demand |
| Technical Support | Direct access to process experts and analytical resources |
Work at our manufacturing site focuses on actual chemical transformation and real-time problem solving rather than abstract commercial promises. Clients have long relied on this approach to navigate pressures in the B2B pharmaceutical value chain. Our accountability to quality, packaging, and on-schedule deliveries stems from direct operational control, forming the backbone for customers who build their business on steady, visible supply.
As a manufacturer with years spent monitoring every stage from synthesis to finished dosage, the engineering behind cilnidipine’s benefits remains a point of pride for our technical team. Cilnidipine acts at the root of hypertension by targeting both L-type and N-type calcium channels. This double-channel action sets cilnidipine apart from earlier calcium channel blockers. By reducing calcium influx into vascular smooth muscle cells, cilnidipine produces a reliable vasodilating effect, helping lower blood pressure.
Beyond the blood vessels, inhibition of N-type calcium channels in sympathetic nerve terminals moderates excessive norepinephrine release. As a result, patients may see fewer issues with rapid heart rate, compared to conventional agents. This mechanism also supports a stable antihypertensive profile over long-term use. Researchers have documented that cilnidipine delivers steady 24-hour blood pressure control, which is essential for patient compliance and reducing cardiovascular risk over time.
Our manufacturing environment follows rigorous process controls designed specifically for heat- and moisture-sensitive actives like cilnidipine. We source high-grade starting materials and monitor every parameter—reaction temperature, solvent quality, particle size—before compression into tablets. This attention to micro-conditions throughout blending and granulation limits impurity formation and maintains product purity. Each tablet batch passes a series of chemical, physical, and microbial tests before it leaves our packaging lines.
The chemical stability of our finished cilnidipine tablets depends heavily on how they’re stored. We seal tablets in high-barrier blisters or HDPE bottles that shield against humidity and light. As direct producers, we strictly recommend keeping tablets at controlled room temperature, ideally below 30°C. Extended exposure to heat or moisture risks changing the physical characteristics of cilnidipine, so we advise our customers to avoid bathroom cabinets, windowsills, or other places with fluctuating temperature and humidity levels.
Facility audits and stability studies have guided the packaging decisions behind every shipment. Each production lot receives stability testing in real-time and accelerated conditions. The product holds its potency and physical structure when stored under recommendations for the established shelf life. By keeping the packs tightly closed and away from sunlight, the risk of degradation stays minimal.
Our distribution partners and in-house logistics team handle final delivery in climate-controlled conditions, minimizing stress on the product before it reaches customers. We do not expose our product to unnecessary risks during transit or storage. Detailed certificates of analysis accompany each shipment, and our team addresses specific requests for documentation related to shelf life, packaging, or recommended storage at any point.
Cilnidipine’s molecular structure and pharmacological benefits require careful consideration at every production and storage step. The proven antihypertensive mechanism, supported by our robust quality systems and carefully designed packaging, ensures that each tablet leaving our facility offers the reliable performance our customers deserve.
Cilnidipine has seen increased interest in global pharmaceutical formulations, especially for hypertension and cardiovascular care. As the direct manufacturer, we’ve shaped our supply approach after years of working with both international and local formulators. The reality of commercial-scale procurement brings up questions about what’s practical, cost-effective, and reliable for bulk buyers. Here’s how we approach pack sizes, minimum order quantities, and production planning at the source.
In high-grade pharmaceutical actives manufacturing, packaging does more than shield the material—it streamlines logistics for the downstream blender and provides traceability for regulatory compliance. We typically provide Cilnidipine in fiber drums with double-layered polyethylene liners, built for both product integrity and manageable handling. Our standard drum sizes hold 25 kg, which allows both large-scale and mid-sized formulators to adapt easily without over-committing on space or incurring waste. These aren’t arbitrary volumes—decades of hands-on experience with end users have shaped these choices to keep inventories in check without disrupting production schedules.
We recognize some customers request smaller test batches or require specific packaging modifications. Our on-site filling lines allow for flexible down-packaging, especially during early project stages, although the most cost-efficient option remains the 25 kg drum. Adapting packaging for specialty requirements is always an option, especially for partners with long-term forecasts or pipeline projects in registration stages.
The MOQ on Cilnidipine reflects more than just the direct material. Running a full synthesis campaign involves validated changeovers, extensive documentation, and rigorous QC at every batch. Based on our production protocols, the practical MOQ for commercial lots starts at 25 kg, essentially one drum. This ensures process reproducibility and batch traceability, as well as realistic use of our reactor lines and purification equipment. Smaller trial samples of a few hundred grams or one kilo are available from campaign retention lots for analytical or formulation evaluation, but regular commercial supply starts at MOQ batch size due to economies of scale.
Our manufacturing site operates with rolling production planning, always guided by forecast visibility and ongoing contract commitments. With Cilnidipine, typical lead times for repeat orders fall in the 3–5 week range once all specifications are aligned and regulatory documents are in place. New customer onboarding, tech transfer, or document reviews (like DMF access or regulatory filings) can add time upfront. For major volume planned orders, we coordinate campaign scheduling so projects integrate with other high-volume APIs, allowing chemical synthesis, purification, and QA release steps to flow without bottlenecks.
We’ve worked through issues like solvent recovery optimization, impurity profiling, and stability studies that can slow turnaround elsewhere. These investments translate into tighter lead time adherence and consistent results. As global demand patterns change, our planning team maintains safety-stock protocols and builds in surge capacity where strategic partners provide regular volume signals. Direct communication between technical, production, and commercial teams drives this process so supply keeps pace with regulatory submission cycles and market launches.
By keeping everything in-house, from reaction monitoring to last-mile packing, we maintain full accountability for timelines. Our commitment reflects a straightforward promise: practical pack sizes, realistic minimums, and predictable lead times, with the traceability and technical support buyers expect from a true pharmaceutical manufacturer.
At our manufacturing facility, every batch of Cilnidipine passes through a controlled and documented process designed to comply with strict regulatory frameworks. We understand the expectations of the global pharmaceutical market, and this drives the commitment behind each shipment leaving our production site. Our plant operates under Good Manufacturing Practice (GMP) guidelines, which form the backbone for ensuring consistently high quality. Strict production records, validated equipment, in-process controls, and trained personnel all play a central role during manufacture.
We hold GMP certification granted by the relevant national authority, and audit trails are thorough and regularly evaluated. Many of our clients require evidence of compliance with the World Health Organization's GMP standards, commonly known as WHO-GMP. Our technical documentation demonstrates alignment with these protocols, backed by process validation reports, batch manufacturing records, and internal and external audit summaries.
Pharmaceutical buyers and regulatory officials worldwide expect robust quality assurance. Without formal recognition of GMP status, Cilnidipine manufacturers face challenges not only from a reputational perspective but also in the practical logistics of export. GMP-compliant production is the foundation for regulatory acceptance in several target markets. Our partners in regulatory affairs keep certification files current, and we provide authenticated copies for every export consignment where requested.
End-to-end traceability and batch-level documentation offer more than compliance — they shield our partners from regulatory risk. Our organization has invested significantly in documented cleaning protocols, raw material traceability, and validated analytical methods. This begins with incoming material inspection and continues through finished product analysis in our quality control labs. All critical manufacturing operations and quality control check-points are documented, ensuring that regulatory bodies have full transparency over our supply chain.
Exporting Cilnidipine requires far more than a Certificate of Analysis. We generate a comprehensive regulatory and shipping portfolio tailored to the requirements of the destination country. Our standard documentation includes the Certificate of Analysis, Certificate of Origin, GMP and/or WHO-GMP certificates, Method of Analysis, and a detailed packing list. For countries demanding stricter oversight, we also supply a Certificate of Pharmaceutical Product (CoPP) along with supporting stability data and relevant regulatory submission documents.
Our export team keeps up to date with changes in international shipping regulations affecting pharmaceuticals. Every shipment undergoes pre-dispatch inspection. Commercial invoices, bill of lading or airway bills, and product-specific Material Safety Data Sheets are included to streamline customs clearance and regulatory review. Regulatory dossiers can be provided where local registration is required. Our team assists in compiling and certifying export documents according to evolving destination market guidelines to avoid costly delays and minimize compliance risk.
We recognize that client and authority requirements are not static. Our quality and technical teams monitor updates in international guidance and continuously adapt practices as required by new laws or customer standards. Whether it concerns Good Distribution Practice (GDP) questions, serialization, or environmental protocols, we ensure readiness for inspection and audit. By maintaining a responsive export documentation process and a transparent GMP compliance culture, we help our partners access global markets with confidence in every batch of our Cilnidipine product.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
